References
- US Food and Drug Administration. Drugs@FDA glossary of terms. Silver Spring (MD): US Department of Health and Human Services; 2012 [updated 2012 Feb 2; cited 2016 Dec 20]. Available from: http://www.fda.gov/drugs/informationondrugs/ucm079436.htm#B
- Generics and Biosimilars Initiative (GaBi) Online. Small molecule versus biological drugs. Mol: Pro PharmaCommunications International; 2012 [updated 2012 Jun 29; cited 2016 Dec 20]. Available from: http://www.gabionline.net/Biosimilars/Research/Small-molecule-versus-biological-drugs
- Medscape Medical News. 100 Best-selling, most prescribed branded drugs through June. New York (NY): WebMD LLC; 2015 [updated 2015 Aug 15; cited 2016 Dec 20]. Available from: http://www.medscape.com/viewarticle/849457
- Mocsai A, Kovacs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43. Epub 2014/03/14
- Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27:55–62. Epub 2014/11/21
- Siebert S, Tsoukas A, Robertson J, et al. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67:280–309. Epub 2015/02/24
- Sridharan M, Hubbard JM, Grothey A. Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology (Williston Park, N.Y.). 2014;28:110–118. Epub 2014/04/08
- F. Hoffmann-La Roche Ltd. MabThera (rituximab) summary of product characteristics. Basel: European Medicines Agency; 2008 [updated 2016 Aug 2; cited 2016 Nov 9]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf
- Genentech Inc. Rituxan® (rituximab) prescribing information. South San Francisco (CA); 1997 [updated 2016 Apr; cited 2016 Dec 14]. Available from: http://www.gene.com/download/pdf/rituxan_prescribing.pdf
- Genentech Inc. Avastin® (bevacizumab) prescribing information. South San Francisco (CA): Genentech Inc; 2004 [updated 2016 Dec; cited 2016 Dec 14]. Available from: http://www.gene.com/download/pdf/avastin_prescribing.pdf
- F. Hoffmann-La Roche Ltd. Avastin (bevacizumab) summary of product characteristics. Basel: European Medicines Agency; 2015 [updated 2016 Jul 19; cited 2016 Dec 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf
- International Council on Harmonisation (ICH). Comparability of biotechnological/biological products subject to changes in their manufacturing process (Q5E): quality of biotechnological products. Geneva: ICH; 2005 [updated 2004 Nov; cited 2016 Dec 20]. Available from: http://www.ich.org/products/guidelines/quality/quality-single/article/comparability-of-biotechnologicalbiological-products-subject-to-changes-in-their-manufacturing-proc.html
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2015 [updated 2015 Apr; cited 2016 Dec 20]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf
- Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract. 2001;14:362–367. Epub 2001/09/27
- Nitin Kashyap U, Gupta V, Raghunandan HV. Comparison of drug approval process in United States & Europe. J Pharm Sci Res. 2013;5:131–136.
- US Food and Drug Administration. How drugs are developed and approved. Silver Spring (MD): US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER); 2015 [updated 2015 Aug 18; cited 2016 Dec 20]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm
- US Food and Drug Administration. New Drug Application (NDA). Silver Spring (MD): US Department of Health and Human Services; 2016 [cited 2016 Dec 20]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm
- International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47:45–50. Epub 2001/10/09
- US Food and Drug Administration. Frequently asked questions on patents and exclusivity. Silver Spring (MD): US Department of Health and Human Services; 2014 [updated 2016 Dec 5; cited 2016 Dec 20]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm
- Brown & Michaels PC. How do I figure out if a US patent is still in force? Ithica (NY): Brown & Michaels PC; 2015 [cited 2016 Dec 20]. Available from: http://www.bpmlegal.com/howtoterm.html
- European Medicines Agency. Data exclusivity, market protection and paediatric rewards. Workshop for micro, small, and medium sized enterprises. London: European Medicines Agency Regulatory Affairs; 2013 [updated 2013 Apr 26; cited 2016 Oct 5]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/05/WC500143122.pdf
- US Food and Drug Administration. Abbreviated New Drug Application (ANDA): generics. Silver Spring (MD): US Department of Health and Human Services; 2016 [cited 2016 Jul 13]. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/default.htm
- European Medicines Agency. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). London: European Medicines Agency; 2014 [updated 2014 Oct 23; cited 2016 Dec 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- Health Canada. Information and submission requirements for biosimilar biologic drugs. Ottawa (ON): Ministry of Health Products and Food Branch; 2016 [updated 2016 Nov 14; cited 2017Mar 2]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2016-eng.pdf
- World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: Expert Committee on Biological Standardization; 2009 [updated 2009 Oct 23; cited 2016 Jun 10]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
- Zuniga L, Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol. 2010;56:374–377. Epub 2009/11/21
- Socinski MA, Curigliano G, Jacobs I, et al. Clinical considerations for the development of biosimilars in oncology. Mabs. 2015;7:286–293. Epub 2015/01/27
- Azevedo V, Hassett B, Fonseca JE, et al. Differentiating biosimilarity and comparability in biotherapeutics. Clinical Rheumatology. 2016;35:2877–2886. Epub 2016/10/14
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency; 2014 [updated 2014 Dec 18; cited 2017 Mar 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- European Medicines Agency. European public assessment report (EPAR) summary of product characteristics: Remicade (infliximab). London: European Medicines Agency Committee of Medicinal Products for Human USE (CHMP); 2009 [updated 2015 Nov 26; cited 2016 Dec 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf
- Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58–64. Epub 2015/09/01
- European Medicines Agency. European public assessment report (EPAR) summary of product characteristics: flixabi (infliximab). Chertsey: Samsung Bioepis UK Limited; 2016 [updated 2016 Nov 15; cited 2017 Mar 6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004020/WC500208356.pdf
- Macdonald JC, Hartman H, Jacobs IA. Regulatory considerations in oncologic biosimilar drug development. Mabs. 2015;7:653–661. Epub 2015/05/12
- Generics and Biosimilars Initiative (GaBI) Online. Biosimilar infliximab launched in Japan [media release]. Mol: Pro PharmaCommunications International; 2014 [updated 2014 Dec 5; cited 2016 May 10]. Available from: http://www.gabionline.net/Biosimilars/News/Biosimilar-infliximab-launched-in-Japan
- Baer IWH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7:530–544. Epub 2014/05/09
- Lammers P, Criscitiello C, Curigliano G, et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014;7:943–953. Epub 2014/09/19
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–417. Epub 2012/02/10
- European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars [press release]. London: European Medicines Agency; 2013 [updated 2013 Jun 28; cited 2016 Dec 20]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1
- Generics and Biosimilars Initiative (GaBi) Online. Biosimilars approved in Europe. Mol: Pro PharmaCommunications International; 2016 [updated 2016 Nov 25; cited 2016 Dec 20]. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
- Biogen, Samsung BioLogics. BENEPALI®, the first etanercept biosimilar referencing Enbrel®, approved in the European Union. Zug: Business Wire; 2016 [updated 2016 Jan 16; cited 2016 Dec 20]. Available from: http://www.businesswire.com/news/home/20160116005011/en/BENEPALI%C2%AE-Etanercept-Biosimilar-Referencing-Enbrel%C2%AE-Approved-European
- US Food and Drug Administration. FDA approves first biosimilar product Zarxio [media release]. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration; 2015 [updated 2015 Mar 6; cited 2016 May 11]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm
- US Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. Silver Spring (MD): US Department of Health and Human Services; 2016 [updated 2016 Apr 5; cited 2016 Jun 17]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm
- US Food and Drug Administration. FDA approves Amjevita, a biosimilar to Humira. Silver Spring (MD): US Department of Health and Human Services; 2016 [updated 2016 Sep 23; cited 2016 Sep 25]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm522243.htm
- Generics and Biosimilars Initiative (GaBi) Online. US$67 billion worth of biosimilar patents expiring before 2020. Mol: Pro PharmaCommunications International; [ updated 2014 Jan 20; cited 2016 Dec 20]. Available from: http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020
- Genetic Engineering & Biotechnology News. Biosimilars: 11 drugs to watch. New Rochelle (NY): GEN; 2014 [updated 2014 May 19; cited 2016 Dec 20]. Available from: http://www.genengnews.com/insight-and-intelligence/biosimilars-11-drugs-to-watch/77900135
- IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets. Parsippany (NJ): IMS Institute foor Healthcare Informatics; 2014 [updated 2014 Oct; cited 2016 Dec 20]. Available from: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf
- Araujo FC, Goncalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them?. Curr Rheumatol Rep. 2016;18:50. Epub 2016/07/13
- Bocquet F, Loubiere A, Fusier I, et al. Competition between biosimilars and patented biologics: learning from European and Japanese experience. PharmacoEconomics. 2016;34:1173–1186. Epub 2016/10/22
- IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. Parsippany (NJ): IMS Institute for Healthcare Informatics; 2016 [updated 2016 Mar; cited 2016 Dec 20]. Available from: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf
- US Food and Drug Administration. Zarxio (filgrastim-sndz) drug approval review documents. Silver Spring (MD): US Department of Health and Human Services; 2015 [updated 2015 Mar 6; cited 2016 Dec 20]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm.
- Sorgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs. 2015;29:123–131. Epub 2015/04/04
- Blackwell K, Semiglazov V, Krasnozhon D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26:1948–1953. Epub 2015/07/01
- Holzmann J, Balser S, Windisch J. Totality of the evidence at work: the first U.S. biosimilar. Expert Opin Biol Ther. 2016;16:137–142. Epub 2015/12/05
- Fang J, Doneanu C, Alley WR Jr., et al. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.. Mabs. 2016;8:1021–1034. Epub 2016/06/05
- Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). Mabs. 2017;9:364–382. Epub 2016/12/23
- Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. Mabs. 2014;6:1163–1177. Epub 2014/12/18
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. Epub 2013/05/21
- Park W, Lee SJ, Yun J, et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, phase I study. Expert Rev Clin Immunol. 2015;11(Suppl 1):S25–31. Epub 2015/09/24
- Shin D, Kim Y, Kim YS, et al. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade(®)) in healthy subjects. BioDrugs. 2015;29:381–388. Epub 2015/11/19
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. Epub 2013/05/21
- Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. Jama. 2017;317:37–47. Epub 2016/12/06
- Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013;27:495–507. Epub 2013/05/08
- US Food and Drug Administration. Nonproprietary naming of biological products. Guidance for industry. FINAL GUIDANCE. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2017 [updated 2017 Jan; cited 2017 Mar 2]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm459987.pdf
- World Health Organization. World Health Organization programme on international nonproprietary names. Biological qualifier: an INN proposal. Geneva: World Health Organization; 2015 [updated 2015 Oct; cited 2016 Dec 14]. Available from: http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf?ua=1
- European Commission Health and Consumers Directorate General. Pharm 639. Summary record. Pharmaceutical Committee 71st Meeting; 2013 [updated 2013 Oct 23; cited 2017 Mar 2]. Available from: http://ec.europa.eu/health/sites/health/files/files/committee/71meeting/pharm639_summary.pdf
- European Medicines Agency. QRD general principles regarding the SmPC information for a generic/hybrid/biosimilar product. London: European Medicines Agency; 2012 [updated 2012 May 3; cited 2016 Dec 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/05/WC500127589.pdf
- US Food and Drug Administration. Labeling for biosimilar products guidance for industry. Draft guidance; 2016 [updated 2016 Mar; cited 2016 Dec 20]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM493439.pdf
- US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry. DRAFT GUIDANCE. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2017 [updated 2017 Jan; cited 2017 Mar 2]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
- Tothfalusi L, Endrenyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ. 2014;15(Suppl 1):S5–11. Epub 2014/05/17
- Renwick MJ, Smolina K, Gladstone EJ, et al. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17:e31–8. Epub 2016/01/14
- Griffith N, McBride A, Stevenson JG, et al. Formulary selection criteria for biosimilars: considerations for US health-system pharmacists. Hosp Pharm. 2014;49:813–825. Epub 2014/12/06
- Ventola CL. Evaluation of biosimilars for formulary inclusion: factors for consideration by P&T committees. P T. 2015;40:680–689. Epub 2015/11/05
- Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf. 2010;19:661–669. Epub 2010/06/29
- European Medicines Agency. European public assessment reports (EPAR): human medicines. London: EMA; 2016 [updated 2016 Sep 15; cited 2016 Dec 20]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit
- US Food and Drug Administration. Drugs@ FDA: FDA approved drug products. Silver Spring (MD): US Department of Health and Human Services; 2016 [cited 2016 Dec 20]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
- Genetic Engineering & Biotechnology News. Biosimilars: 10 drugs to watch. New Rochelle (NY): GEN; 2013 [updated 2013 Apr 29; cited 2016 Dec 20]. Available from: http://www.genengnews.com/insight-and-intelligence/biosimilars-10-drugs-to-watch/77899804
- Generics and Biosimilars Initiative (GaBi) Online. Finox submits r-FSH biosimilar application to EMA. Mol: Pro PharmaCommunications International; 2013 [updated 2013 Jan 18; cited 2016 Nov 9]. Available from: http://gabionline.net/Biosimilars/News/Finox-submits-r-FSH-biosimilar-application-to-EMA